Markets · News reference
Filed: 2026-09-09 AccNo: 0001193125-26-385584 Size: 230 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
No ticker was attached by the source feed.
Keep reading
On Thursday, Copart (NASDAQ:CPRT) discussed fourth-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings call transcripts and
North American Construction Group Ltd. ("NACG" or "the Company") (TSX:NOA, NYSE:NOA) today announced the appointment of Brad Rogers as the Company’s President and Chief Executive Officer effective
A class action lawsuit has been filed against HDFC Bank Limited for allegedly camouflaging payments as marketing expenses to pay higher interest rates to a state firm to induce deposits. The scheme involved disguising approximately $4.7 million in markup payments as sponsorship fees. The disclosure led to significant stock price declines on March 18, 2026 (7.28%) and May 27, 2026 (4.1%). Investors who purchased HDFC securities between July 17, 2023 and May 26, 2026 may be eligible to participate in the lawsuit.
Chevron is recommended as a resilient oil dividend stock for September due to its diversified upstream, midstream, and downstream operations. With a 3.4% dividend yield, 39 consecutive years of dividend increases, a strong balance sheet ($8.53B cash, 13.1% net debt ratio), and expected 2%-3% annual production growth through 2030, Chevron offers stability even during oil price volatility. Trading at 16x forward earnings with projected 4% revenue and 24% EPS growth (2025-2028), it appears undervalued compared to the S&P 500.
Acumen Pharmaceuticals announced a virtual Investor Day scheduled for September 16, 2026, to discuss its clinical-stage pipeline. The company is advancing sabirnetug (ACU193), a monoclonal antibody targeting toxic amyloid beta oligomers for Alzheimer's disease treatment, with Phase 2 ALTITUDE-AD trial results expected in late 2026. Acumen is also exploring subcutaneous formulations and collaborating with JCR Pharmaceuticals on enhanced brain delivery technologies.
GameStop director James Grube purchased 10,255 shares for approximately $196,000 on September 9, 2026, increasing his direct holdings to 39,694 shares. The purchase is viewed as a bullish signal, as insider buying typically indicates confidence in future stock price appreciation. This comes as GameStop reported strong financial results with net income jumping 77% in Q2, and the company continues to expand into trading cards and collectibles.